Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$14.22
-0.45-3.07%
Pre-Market: 6:07 AM EDT
Comments
Loading...
Viridian Therapeutics Analyst Ratings and Price Targets | NASDAQ:VRDN | Benzinga
Viridian Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Viridian Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Wells Fargo
RBC Capital
HC Wainwright & Co.
BTIG
1calculated from analyst ratings
Analyst Ratings for Viridian Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/07/2025 | Buy Now | — | Needham | Serge Belanger68% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2024 | Buy Now | — | Wells Fargo | Derek Archila58% | → $27 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/17/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $44 → $47 | Maintains | Outperform | Get Alert |
| 12/17/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 12/16/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $34 → $34 | Reiterates | Buy → Buy | Get Alert |
| 12/05/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $44 → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 11/25/2024 | Buy Now | — | Needham | Serge Belanger68% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | — | TD Cowen | Joseph Thome34% | — | Initiates | → Buy | Get Alert |
| 11/14/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $27 → $34 | Maintains | Buy | Get Alert |
| 11/13/2024 | Buy Now | — | Needham | Serge Belanger68% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 10/28/2024 | Buy Now | — | Needham | Serge Belanger68% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 09/26/2024 | Buy Now | — | BTIG | Julian Harrison41% | $56 → $61 | Maintains | Buy | Get Alert |
| 09/19/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $44 → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 09/13/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $35 → $44 | Maintains | Outperform | Get Alert |
| 09/12/2024 | Buy Now | — | Goldman Sachs | Richard Law45% | $25 → $31 | Maintains | Buy | Get Alert |
| 09/11/2024 | Buy Now | — | Needham | Serge Belanger68% | $30 → $38 | Maintains | Buy | Get Alert |
| 09/10/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 09/10/2024 | Buy Now | — | BTIG | Julian Harrison41% | $46 → $56 | Maintains | Buy | Get Alert |
| 08/30/2024 | Buy Now | — | Needham | Serge Belanger68% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2024 | Buy Now | — | RBC Capital | Gregory Renza48% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | — | Oppenheimer | Leland Gershell69% | $31 → $28 | Reiterates | Outperform → Outperform | Get Alert |
| 07/29/2024 | Buy Now | — | Wedbush | Laura Chico47% | $42 → $42 | Reiterates | Outperform → Outperform | Get Alert |
| 07/16/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $27 → $27 | Reiterates | Buy → Buy | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen40% | — | Initiates | → Outperform | Get Alert |
| 06/11/2024 | Buy Now | — | Needham | Serge Belanger68% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2024 | Buy Now | — | Goldman Sachs | Richard Law45% | → $23 | Initiates | → Buy | Get Alert |
| 05/09/2024 | Buy Now | — | Needham | Serge Belanger68% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $37 → $27 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | — | Oppenheimer | Leland Gershell69% | $36 → $31 | Maintains | Outperform | Get Alert |
| 05/09/2024 | Buy Now | — | Ladenburg Thalmann | Michael Higgins47% | — | Downgrade | Buy → Neutral | Get Alert |
| 05/09/2024 | Buy Now | — | B. Riley Securities | Kalpit Patel39% | $25 → $20 | Downgrade | Buy → Neutral | Get Alert |
| 03/21/2024 | Buy Now | — | B. Riley Securities | Kalpit Patel39% | $29 → $25 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | — | Needham | Serge Belanger68% | $30 → $30 | Maintains | Buy | Get Alert |
| 02/29/2024 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | — | Needham | Serge Belanger68% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | — | Wedbush | Laura Chico47% | $39 → $40 | Maintains | Outperform | Get Alert |
| 12/19/2023 | Buy Now | — | Oppenheimer | Leland Gershell69% | $35 → $36 | Maintains | Outperform | Get Alert |
| 12/18/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
| 12/14/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | $35 → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 12/04/2023 | Buy Now | — | Wedbush | Laura Chico47% | → $37 | Reiterates | Outperform → Outperform | Get Alert |
| 11/14/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $35 | Reiterates | Outperform → Outperform | Get Alert |
| 11/14/2023 | Buy Now | — | JMP Securities | Jason Butler56% | $42 → $38 | Maintains | Market Outperform | Get Alert |
| 10/31/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | $44 → $35 | Maintains | Outperform | Get Alert |
| 10/31/2023 | Buy Now | — | Wedbush | Laura Chico47% | $46 → $37 | Maintains | Outperform | Get Alert |
| 10/30/2023 | Buy Now | — | Needham | Serge Belanger68% | $40 → $30 | Maintains | Buy | Get Alert |
| 09/13/2023 | Buy Now | — | Stifel | Alex Thompson46% | → $40 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | — | Wedbush | Laura Chico47% | → $46 | Reiterates | Outperform → Outperform | Get Alert |
| 08/10/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $40 → $37 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | — | Needham | Serge Belanger68% | $47 → $40 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | — | JMP Securities | Jason Butler56% | $44 → $42 | Maintains | Market Outperform | Get Alert |
| 08/09/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 08/09/2023 | Buy Now | — | Wells Fargo | — | $46 → $39 | Maintains | Overweight | Get Alert |
| 08/09/2023 | Buy Now | — | Oppenheimer | Leland Gershell69% | $40 → $35 | Maintains | Outperform | Get Alert |
| 07/11/2023 | Buy Now | — | Wedbush | Laura Chico47% | $48 → $45 | Maintains | Outperform | Get Alert |
| 07/11/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $44 | Reiterates | Outperform → Outperform | Get Alert |
| 07/11/2023 | Buy Now | — | JMP Securities | Jason Butler56% | → $44 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 07/11/2023 | Buy Now | — | Needham | Serge Belanger68% | → $47 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | → $40 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | Buy Now | — | BTIG | Julian Harrison41% | → $46 | Initiates | → Buy | Get Alert |
| 06/14/2023 | Buy Now | — | Credit Suisse | Tiago Fauth42% | → $51 | Assumes | → Outperform | Get Alert |
| 05/30/2023 | Buy Now | — | RBC Capital | Gregory Renza48% | → $44 | Initiates | → Outperform | Get Alert |
| 05/10/2023 | Buy Now | — | Oppenheimer | Leland Gershell69% | $45 → $40 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | — | Wedbush | Laura Chico47% | $46 → $48 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | — | Credit Suisse | Tiago Fauth42% | → $51 | Reiterates | → Outperform | Get Alert |
| 05/10/2023 | Buy Now | — | JMP Securities | Jason Butler56% | $46 → $44 | Maintains | Market Outperform | Get Alert |
| 05/10/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | → $40 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | — | Wells Fargo | — | → $46 | Initiates | → Overweight | Get Alert |
| 04/10/2023 | Buy Now | — | Needham | Serge Belanger68% | → $47 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | — | Stifel | Alex Thompson46% | → $49 | Initiates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | — | Ladenburg Thalmann | Michael Higgins47% | → $40 | Reiterates | → Buy | Get Alert |
| 03/09/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | $35 → $40 | Maintains | Buy | Get Alert |
| 02/07/2023 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | → $35 | Reiterates | → Buy | Get Alert |
| 01/09/2023 | Buy Now | — | SVB Leerink | Thomas Smith33% | $40 → $45 | Maintains | Outperform | Get Alert |
| 12/19/2022 | Buy Now | — | Needham | Serge Belanger68% | → $45 | Initiates | → Buy | Get Alert |
| 12/16/2022 | Buy Now | — | Credit Suisse | Tiago Fauth42% | → $51 | Initiates | → Outperform | Get Alert |
| 12/01/2022 | Buy Now | — | HC Wainwright & Co. | Douglas Tsao52% | → $35 | Initiates | → Buy | Get Alert |
| 11/15/2022 | Buy Now | — | JMP Securities | Jason Butler56% | $47 → $46 | Maintains | Market Outperform | Get Alert |
| 08/16/2022 | Buy Now | — | Ladenburg Thalmann | Michael Higgins47% | $33 → $40 | Maintains | Buy | Get Alert |
| 08/15/2022 | Buy Now | — | SVB Leerink | Mike Kratky66% | $32 → $40 | Maintains | Outperform | Get Alert |
| 06/23/2022 | Buy Now | — | B. Riley Securities | Kalpit Patel39% | → $25 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Viridian Therapeutics (VRDN) stock?
The latest price target for Viridian Therapeutics (NASDAQ:VRDN) was reported by Needham on January 7, 2025. The analyst firm set a price target for $38.00 expecting VRDN to rise to within 12 months (a possible 167.23% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viridian Therapeutics (VRDN)?
The latest analyst rating for Viridian Therapeutics (NASDAQ:VRDN) was provided by Needham, and Viridian Therapeutics reiterated their buy rating.
When was the last upgrade for Viridian Therapeutics (VRDN)?
There is no last upgrade for Viridian Therapeutics
When was the last downgrade for Viridian Therapeutics (VRDN)?
The last downgrade for Viridian Therapeutics Inc happened on December 19, 2024 when Wells Fargo changed their price target from N/A to $27 for Viridian Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Viridian Therapeutics (VRDN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viridian Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viridian Therapeutics was filed on January 7, 2025 so you should expect the next rating to be made available sometime around January 7, 2026.
Is the Analyst Rating Viridian Therapeutics (VRDN) correct?
While ratings are subjective and will change, the latest Viridian Therapeutics (VRDN) rating was a reiterated with a price target of $38.00 to $38.00. The current price Viridian Therapeutics (VRDN) is trading at is $14.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.